Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Downregulation of IRF7-mediated type-I interferon response by LmCen ^-/- parasites is necessary for protective immunity.

Autor: Sepahpour T; Division of Emerging and Transfusion Transmitted Diseases, CBER, FDA, Silver Spring, MD, 20993, USA., Alshaweesh J; Department of Parasitology, Institute of Tropical Medicine (NEKKEN), The Joint Usage/Research Center on Tropical Disease, Nagasaki University, Nagasaki, Japan, and Graduate School of Biomedical Sciences, Doctoral Leadership Program, Nagasaki University, Nagasaki, Japan., Azodi N; Division of Emerging and Transfusion Transmitted Diseases, CBER, FDA, Silver Spring, MD, 20993, USA., Singh K; National Heart Lung Blood Institute (NHLBI), NIH, Bethesda, MD, USA., Ireland DDC; Office of Pharmaceutical Quality, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD, USA., Valanezhad F; Department of Parasitology, Institute of Tropical Medicine (NEKKEN), The Joint Usage/Research Center on Tropical Disease, Nagasaki University, Nagasaki, Japan, and Graduate School of Biomedical Sciences, Doctoral Leadership Program, Nagasaki University, Nagasaki, Japan., Nakamura R; Department of Parasitology, Institute of Tropical Medicine (NEKKEN), The Joint Usage/Research Center on Tropical Disease, Nagasaki University, Nagasaki, Japan, and Graduate School of Biomedical Sciences, Doctoral Leadership Program, Nagasaki University, Nagasaki, Japan., Satoskar AR; Department of Pathology and Microbiology, Ohio State University, Columbus, OH, USA., Dey R; Division of Emerging and Transfusion Transmitted Diseases, CBER, FDA, Silver Spring, MD, 20993, USA. Ranadhir.dey@fda.hhs.gov., Hamano S; Department of Parasitology, Institute of Tropical Medicine (NEKKEN), The Joint Usage/Research Center on Tropical Disease, Nagasaki University, Nagasaki, Japan, and Graduate School of Biomedical Sciences, Doctoral Leadership Program, Nagasaki University, Nagasaki, Japan. shinjiro@nagasaki-u.ac.jp., Nakhasi HL; Division of Emerging and Transfusion Transmitted Diseases, CBER, FDA, Silver Spring, MD, 20993, USA. Hira.nakhasi@fda.hhs.gov., Gannavaram S; Division of Emerging and Transfusion Transmitted Diseases, CBER, FDA, Silver Spring, MD, 20993, USA. Sreenivas.gannavaram@fda.hhs.gov.

Publikováno v: NPJ vaccines [NPJ Vaccines] 2024 Dec 19; Vol. 9 (1), pp. 250. Date of Electronic Publication: 2024 Dec 19.